COMP <GO>
QDEL vs CLDX // ALTMAN Z-SCORE & DEBT/EQUITY
QuidelOrtho Corporation (NASDAQ) VS. Celldex Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: QDEL 6
— CLDX 2
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: CLDX
LAST: $13.76 (-1.78%) • MKT CAP: $943.6M
balance-sheet
0.20
LAST: $29.89 (+0.78%) • MKT CAP: $2.35B
balance-sheet
20.25
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QDEL VS. CLDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QDEL | CLDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 87.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.80% | -9.10% | +0.30 | QDEL | /fcf-yield <GO> |
| Operating Margin | -33.70% | -60.00% | +26.30 | QDEL | /operating-margins <GO> |
| Net Profit Margin | -41.50% | -60.00% | +18.50 | QDEL | /net-margins <GO> |
| Revenue Growth (YoY) | -1.90% | -65.00% | +63.10 | QDEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 0.20 | 20.25 | -20.05 | CLDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | QDEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 45.5 | +5.62 | QDEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $943.6M | $2.35B | -$1.40B | CLDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QDEL REV | CLDX REV | QDEL GROSS % | CLDX GROSS % | QDEL FCF | CLDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.73B | $1.5M | — | 87.1% | -$83.0M | -$213.7M |
| FY 2024 | $2.78B | $7.0M | — | 97.2% | -$112.1M | -$159.7M |
| FY 2023 | $3.00B | $6.9M | — | — | $280.2M | -$107.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QDEL // BETA —
CLDX // BETA —